Jacobio Pharmaceuticals Group Co. Ltd. has announced a licence and collaboration agreement with AstraZeneca AB for the development and commercialization of the pan-KRAS inhibitor JAB-23E73. Under the agreement, Jacobio's subsidiary, Beijing Jacobio, will receive an upfront payment of US$100 million from AstraZeneca and may receive additional milestone payments totaling up to US$1.915 billion, contingent on the achievement of certain development, regulatory, and commercial milestones. AstraZeneca will lead the development and commercialization of JAB-23E73 outside of mainland China, while the two companies will jointly develop and co-commercialize the product within mainland China.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251221-11962696), on December 21, 2025, and is solely responsible for the information contained therein.